Biohaven announces Expanded Access Program for Patients with ALS
91Ï㽶ÊÓƵ’s partner, Biohaven, announces it has Initiated Expanded Access Program for Sublingual BHV-0223 ZYDIS® Orally Dissolving Tablets for Patients with Amyotrophic Lateral Sclerosis (ALS)